Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Variation in oral calcitriol response in patients with stages 3-4 CKD.

Shoben AB, Levin G, de Boer IH, Yeung C, Watnick S, Ayers E, Kestenbaum B.

Am J Kidney Dis. 2012 May;59(5):645-52. doi: 10.1053/j.ajkd.2011.11.041. Epub 2012 Jan 29.

2.

[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].

Lorenzo Sellares V, Torregrosa V.

Nefrologia. 2008;28 Suppl 3:67-78. Spanish.

3.

Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.

Zisman AL, Hristova M, Ho LT, Sprague SM.

Am J Nephrol. 2007;27(1):36-43. Epub 2007 Jan 11.

PMID:
17215573
4.

Interventions for metabolic bone disease in children with chronic kidney disease.

Hahn D, Hodson EM, Craig JC.

Cochrane Database Syst Rev. 2015 Nov 12;(11):CD008327. doi: 10.1002/14651858.CD008327.pub2. Review.

PMID:
26561037
5.

Association of oral calcitriol with improved survival in nondialyzed CKD.

Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B.

J Am Soc Nephrol. 2008 Aug;19(8):1613-9. doi: 10.1681/ASN.2007111164. Epub 2008 May 7.

6.

Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD.

Al-Aly Z, Qazi RA, González EA, Zeringue A, Martin KJ.

Am J Kidney Dis. 2007 Jul;50(1):59-68.

PMID:
17591525
7.

Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD.

Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA.

Kidney Int. 1994 Jun;45(6):1710-21.

8.

Vitamin D treatment in hemodialysis patients with low serum levels of parathyroid hormone: which is the best choice?

Lomonte C, Casucci F, Libutti P, Losurdo N, Teutonico A, Basile C.

J Nephrol. 2010 Mar-Apr;23(2):210-5.

PMID:
20175051
9.

Control of parathyroid function in patients with a short history of hemodialysis.

Nishi H, Sato T, Kurihara T, Kurosawa T, Fukagawa M.

Ther Apher Dial. 2005 Feb;9(1):39-43.

PMID:
15828904
10.

Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.

Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wüthrich RP, Russmann S, Serra AL.

Nephrol Dial Transplant. 2013 Feb;28(2):352-9. doi: 10.1093/ndt/gfs460. Epub 2012 Nov 4.

11.

Parathyroid hormone suppression by intravenous calcitriol: role of phosphate, calcium, race and diabetes.

Kant KS, Cook EF, Duncan H, Freyberg R.

Am J Med Sci. 2002 Apr;323(4):210-5.

PMID:
12003377
12.

Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).

Bhuriya R, Li S, Chen SC, McCullough PA, Bakris GL.

Am J Kidney Dis. 2009 Apr;53(4 Suppl 4):S3-10. doi: 10.1053/j.ajkd.2008.11.029.

PMID:
19285609
13.

Association of serum intact parathyroid hormone with lower estimated glomerular filtration rate.

Muntner P, Jones TM, Hyre AD, Melamed ML, Alper A, Raggi P, Leonard MB.

Clin J Am Soc Nephrol. 2009 Jan;4(1):186-94. doi: 10.2215/CJN.03050608. Epub 2008 Nov 19.

14.

Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.

Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, Williams ME, Bishop CW.

Am J Kidney Dis. 2004 May;43(5):877-90.

PMID:
15112179
15.

Effect of calcitriol and age on recovery from hypocalcemia in hemodialysis patients.

Borrego MJ, Martin-Malo A, Almaden Y, Rodriguez M, Aljama P, Felsenfeld AJ.

Am J Kidney Dis. 1999 Sep;34(3):456-63.

PMID:
10469855
16.

Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients.

Tomida K, Hamano T, Mikami S, Fujii N, Okada N, Matsui I, Nagasawa Y, Moriyama T, Ito T, Imai E, Isaka Y, Rakugi H.

Bone. 2009 Apr;44(4):678-83. doi: 10.1016/j.bone.2008.11.016. Epub 2008 Dec 9.

PMID:
19111635
17.

Hemoglobin differences by race in children with CKD.

Atkinson MA, Pierce CB, Zack RM, Barletta GM, Yadin O, Mentser M, Warady BA, Furth SL.

Am J Kidney Dis. 2010 Jun;55(6):1009-17. doi: 10.1053/j.ajkd.2009.12.040. Epub 2010 Apr 24.

18.

Vitamin D receptor genotype influences parathyroid hormone and calcitriol levels in predialysis patients.

Marco MP, Martínez I, Amoedo ML, Borràs M, Saracho R, Almirall J, Fibla J, Fernández E.

Kidney Int. 1999 Oct;56(4):1349-53.

19.

Parathyroid hormone may be an early predictor of low serum hemoglobin concentration in patients with not advanced stages of chronic kidney disease.

Russo D, Morrone L, Di Iorio B, Andreucci M, De Gregorio MG, Errichiello C, Russo L, Locatelli F.

J Nephrol. 2015 Dec;28(6):701-8. doi: 10.1007/s40620-014-0129-1. Epub 2014 Aug 12.

20.

Supplemental Content

Support Center